DE69835524D1 - Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg - Google Patents

Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg

Info

Publication number
DE69835524D1
DE69835524D1 DE69835524T DE69835524T DE69835524D1 DE 69835524 D1 DE69835524 D1 DE 69835524D1 DE 69835524 T DE69835524 T DE 69835524T DE 69835524 T DE69835524 T DE 69835524T DE 69835524 D1 DE69835524 D1 DE 69835524D1
Authority
DE
Germany
Prior art keywords
complement activation
alternative way
inhibiting complement
inhibiting
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69835524T
Other languages
English (en)
Other versions
DE69835524T2 (de
Inventor
Rekha Gupta-Bansal
R Brunden
James B Parent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Fremont Inc
Original Assignee
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Fremont Inc filed Critical Amgen Fremont Inc
Publication of DE69835524D1 publication Critical patent/DE69835524D1/de
Application granted granted Critical
Publication of DE69835524T2 publication Critical patent/DE69835524T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Fats And Perfumes (AREA)
  • External Artificial Organs (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Cereal-Derived Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69835524T 1997-08-26 1998-08-24 Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg Expired - Fee Related DE69835524T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91834997A 1997-08-26 1997-08-26
US918349 1997-08-26
PCT/US1998/017500 WO1999010009A1 (en) 1997-08-26 1998-08-24 A process for inhibiting complement activation via the alternative pathway

Publications (2)

Publication Number Publication Date
DE69835524D1 true DE69835524D1 (de) 2006-09-21
DE69835524T2 DE69835524T2 (de) 2007-04-05

Family

ID=25440234

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835524T Expired - Fee Related DE69835524T2 (de) 1997-08-26 1998-08-24 Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg

Country Status (13)

Country Link
US (3) US6333034B1 (de)
EP (1) EP1007092B1 (de)
JP (1) JP2001513576A (de)
AT (1) ATE335511T1 (de)
AU (1) AU756490B2 (de)
CA (1) CA2302317A1 (de)
DE (1) DE69835524T2 (de)
DK (1) DK1007092T3 (de)
ES (1) ES2270530T3 (de)
NO (1) NO20000935L (de)
NZ (1) NZ503033A (de)
PT (1) PT1007092E (de)
WO (1) WO1999010009A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641571B2 (en) * 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
DK1325033T3 (da) 2000-10-10 2010-04-06 Genentech Inc Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
US20030049260A1 (en) * 2001-07-26 2003-03-13 Leonard Bell Method of improving cognitive function
ES2198216B1 (es) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones.
EP2305812A3 (de) * 2002-11-14 2012-06-06 Dharmacon, Inc. Funktionale und hyperfunktionale siRNA
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
PT1713503E (pt) * 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
US20080050391A1 (en) * 2004-03-30 2008-02-28 Lazarus Alan H Method for Treating Autoimmune Diseases With Antibodies
BRPI0401765C1 (pt) * 2004-05-17 2011-03-15 Hy Biotecnologica Ltda método de enriquecimento de espermatozoides de mamìferos portadores de cromossomo x ou de cromossomo y
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN101227924A (zh) * 2005-05-26 2008-07-23 科罗拉多大学评议会 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
JP2009514888A (ja) * 2005-11-04 2009-04-09 ジェネンテック・インコーポレーテッド 眼疾患を処置するための補体経路の阻害剤の使用
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
ES2524984T3 (es) 2005-11-30 2014-12-16 Abbvie Inc. Anticuerpos anti-globulómero a?, porciones de unión a antígeno de estos, hibridomas correspondientes, ácidos nucleicos, vectores, células huésped, métodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos, usos de dichos anticuerpos, y métodos para usar dichos anticuerpos
HUE026042T2 (en) 2006-10-10 2016-05-30 Regenesance B V Complement inhibition for improved nerve regeneration
TW201534620A (zh) * 2006-11-02 2015-09-16 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
CN101668773B (zh) * 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
US9745367B2 (en) * 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
WO2008154018A2 (en) * 2007-06-11 2008-12-18 The Trustees Of The University Of Pennsylvania Properdin modulation of alternative pathway and uses thereof
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
CN101970002B (zh) 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
US20140127204A1 (en) 2010-09-03 2014-05-08 Novelmed Therapeutics, Inc. Anti-properdin antibodies
PT2262831E (pt) * 2008-03-03 2015-05-18 Novelmed Therapeutics Inc Anticorpos antiproperdina
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2010030789A1 (en) * 2008-09-10 2010-03-18 Novelmed Therapeutics, Inc. Device and method for inhibiting complement activation
US20110262456A1 (en) * 2008-11-14 2011-10-27 Rekha Bansal Method of treating ischemia reperfusion injury
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CN103068396B (zh) * 2010-03-02 2016-07-06 诺沃姆德治疗公司 抑制c5和备解素相互作用的抗-备解素抗体在制备抑制交替途径活化的药剂中的用途
CN103003302B (zh) * 2010-03-10 2015-09-30 诺沃姆德治疗公司 人源化和嵌合抗-备解素抗体
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
CA2840270C (en) 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
WO2013006449A2 (en) 2011-07-01 2013-01-10 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
EP3330288A1 (de) 2011-12-21 2018-06-06 Novartis AG Zusammensetzungen die gegen faktor p gerichtete antikörper enthalten
EP2841453B1 (de) 2012-04-03 2019-11-27 NovelMed Therapeutics, Inc. Humanisierte und chimäre anti-faktor-c3-antikörper und verwendungen davon
EP2855529A4 (de) 2012-05-24 2015-12-09 Alexion Pharma Inc Humanisierte anti-faktor-b-antikörper
CN104870474B (zh) 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
EA201690213A1 (ru) 2013-08-12 2016-07-29 Дженентек, Инк. Композиции и способ лечения связанных с комплементом состояний
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (de) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-faktor-d-antikörper und -konjugate
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
EP3275897A1 (de) * 2016-07-27 2018-01-31 Biotest AG Verfahren zur herstellung von immunoglobulinzusammensetzungen
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US5434075A (en) * 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
EP0751787B1 (de) 1994-03-23 2005-01-12 Alexion Pharmaceuticals, Inc. Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs

Also Published As

Publication number Publication date
WO1999010009A1 (en) 1999-03-04
DK1007092T3 (da) 2006-10-02
JP2001513576A (ja) 2001-09-04
NZ503033A (en) 2003-01-31
DE69835524T2 (de) 2007-04-05
CA2302317A1 (en) 1999-03-04
ATE335511T1 (de) 2006-09-15
EP1007092A1 (de) 2000-06-14
NO20000935L (no) 2000-04-18
AU756490B2 (en) 2003-01-16
ES2270530T3 (es) 2007-04-01
NO20000935D0 (no) 2000-02-25
AU9203398A (en) 1999-03-16
US6333034B1 (en) 2001-12-25
PT1007092E (pt) 2006-12-29
US20020015701A1 (en) 2002-02-07
EP1007092B1 (de) 2006-08-09
US20030198636A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
DE69835524D1 (de) Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
DE69830574D1 (de) Verbesserte verfahren zur herstellung von vernetzt verbrückten macropolycyclen
ATE250066T1 (de) Verfahren zur reduktion von oxiranyl-epothilonen zu olefinischen epothilonen
ES2149514T3 (es) Procedimiento para la obtencion simultanea de capro-lactama y hexametilendiamina.
DE59809789D1 (de) Verfahren zur Herstellung von Propen
DE69203767D1 (de) Verfahren zur Herstellung von organischen Düngemitteln.
DE58908126D1 (de) Verfahren zur Herstellung von Organopolysilanen.
DE69613384D1 (de) Verfahren zur hydrocyanierung von organischen, ethylenisch ungesättigten verbindungen
DE69018178D1 (de) Verfahren zur Herstellung von Disilan.
ATE213005T1 (de) Kontinuierliches polymerisationverfahren von polyamiden
DE69019753D1 (de) Verfahren zur verwendung von gashilfe während des giessens von kunststoffgegenständen.
DE59103454D1 (de) Verfahren zur Herstellung von feinteiligen, wasserlöslichen Polymerisaten.
DE69020172D1 (de) Verfahren zur Herstellung von epsilon-Caprolactam.
BG108682A (en) Method for the production of transparent flexible container, and container produced therewith
ATE268996T1 (de) Verbessertes formverfahren für konfektprodukte
DE69412559D1 (de) Verfahren zur Vergasung von organischen Materien
ATE194602T1 (de) Verfahren zur herstellung von 1,4,7,10- tetraazacyclododecan und dessen derivaten
EA199900741A1 (ru) Способ получения эпросартана
DE59000468D1 (de) Verfahren zur schnellen pruefung der wirksamkeit von agenzien auf mikroorganismen.
DE58907409D1 (de) Verfahren zur Herstellung von Caprolactam.
DE3879843D1 (de) Verfahren zur herstellung von 3,5,5-trimethylcyclohexa-2-en-1,4-dion.
DE68924815D1 (de) Verfahren zur Haftung von aromatischen Polyamiden.
DE59807664D1 (de) Verfahren zur herstellung von 3-cyano-2,4-dihalogen-5-fluor-benzoesäuren
DE58901165D1 (de) Verfahren zur herstellung von 2,4-dihydroxybenzoesaeure.
DE69019890D1 (de) Verfahren zur Produktion von der Spiroplasma sp. DNA Methylase.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee